BRAF and melanoma: In an interesting report, Morales et al. assessed the sensitivity of melanoma cells to the B-Raf inhibitor vemurafenib in a 3D coculture system consisting of metastatic melanoma cells incorporated in a dermal fibroblast-derived matrix scaffold [186].